SEATTLE, Dec. 17, 2021 /PRNewswire/ — Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibody program at the virtual European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021, that took place December 8-11, 2021. Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster revealing compelling in vitro data on the T cell activation and cytokine induction of Kineta’s lead anti-CD27 agonist antibodies. Additionally, Dr. Guillaudeux presented new in vivo data demonstrating strong anti-tumor efficacy as a monotherapy in an MB49 tumor model.
"We are excited to see the robust preclinical data of our anti-CD27 agonist antibodies that was presented at ESMO," said Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta. "These data demonstrate the potential of our future lead anti-CD27 agonist antibodies as a monotherapy. Additionally, we believe there are combinations with other immunotherapies that can provide strong synergistic efficacy and improve outcomes for patients with cancer."
Key results from the ESMO poster presentation:
- Evaluated 15 leads out of 147 fully human anti-CD27 monoclonal antibodies with unique sequences
- Human T cell activation assay showed strong increased in proliferation and cytokine secretion for 3 mAbs
- Surrogate in vivo model with anti-mouse CD27 agonist showed significant anti-tumor response
- huCD27 transgenic mice will serve as our model for further in vivo studies to select our lead anti-CD27 agonist antibody
Title: Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27
shape adaptive anti-tumor immunity
Date Presented: December 8-11, 2021
Presenter: Thierry Guillaudeux, PhD
Poster: Click on the link below to view the poster:
Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q1-Q2 2022.
Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives. We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
SOURCE Kineta, Inc.